Vor Biopharma (NYSE:VOR) Shares Down 5.6% – What’s Next?

Vor Biopharma Inc. (NYSE:VOR) traded down 5.6% on Monday . The stock traded as low as $1.29 and last traded at $1.34. 449,903 shares traded hands during trading, a decline of 45% from the average session volume of 817,967 shares. The stock had previously closed at $1.42.

Analyst Ratings Changes

Several analysts have recently weighed in on the stock. Wedbush reaffirmed an “outperform” rating and set a $11.00 price objective on shares of Vor Biopharma in a report on Monday, December 9th. JMP Securities reaffirmed a “market outperform” rating and set a $12.00 price objective on shares of Vor Biopharma in a report on Tuesday, December 10th. HC Wainwright reaffirmed a “buy” rating and set a $17.50 price objective on shares of Vor Biopharma in a report on Tuesday, December 10th. Finally, Robert W. Baird dropped their price objective on shares of Vor Biopharma from $22.00 to $14.00 and set an “outperform” rating for the company in a report on Friday, November 8th. Seven research analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $11.36.

Vor Biopharma Price Performance

The stock has a market capitalization of $92.02 million, a P/E ratio of -0.81 and a beta of -0.45. The business’s 50 day simple moving average is $1.16 and its 200-day simple moving average is $0.95.

Vor Biopharma (NYSE:VOR) last announced its quarterly earnings data on Thursday, November 7th. The company reported ($0.40) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.40). Research analysts anticipate that Vor Biopharma Inc. will post -1.42 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Vor Biopharma

Hedge funds and other institutional investors have recently made changes to their positions in the company. Hsbc Holdings PLC boosted its position in shares of Vor Biopharma by 177.0% during the second quarter. Hsbc Holdings PLC now owns 49,038 shares of the company’s stock worth $51,000 after purchasing an additional 31,333 shares in the last quarter. Cubist Systematic Strategies LLC bought a new position in shares of Vor Biopharma during the second quarter worth $53,000. Rosalind Advisors Inc. bought a new position in shares of Vor Biopharma during the third quarter worth $54,000. Exchange Traded Concepts LLC boosted its position in shares of Vor Biopharma by 40.8% during the third quarter. Exchange Traded Concepts LLC now owns 165,805 shares of the company’s stock worth $116,000 after purchasing an additional 48,017 shares in the last quarter. Finally, Renaissance Technologies LLC boosted its position in shares of Vor Biopharma by 48.0% during the second quarter. Renaissance Technologies LLC now owns 495,300 shares of the company’s stock worth $495,000 after purchasing an additional 160,642 shares in the last quarter. 97.29% of the stock is owned by institutional investors.

Vor Biopharma Company Profile

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.